CytoDyn Inc. (CytoDyn), a late-stage biotechnology company, announced today that it is currently accepting only 155 more candidates across the country for its Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19. Three of the sites in Texas where CytoDyn is conducting its trial are University of Texas Health in Houston, Baylor College of Medicine in Houston and Baylor Scott & White Health in Dallas. CytoDyn has already registered 235 patients in its trial, and the Data Safety […]